Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

175 та иш

Иш: CAR-T cell combination therapy: the next revolution in cancer treatment

  1. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

    Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

    Мақола20174 иқтибос
    ABI

  2. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

    Miyuki Tanaka, Haruko Tashiro, Bilal Omer +9

    Мақола20173 иқтибос
    ABI

  3. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    Мақола20173 иқтибос
    ABI

  4. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma

    Tobias Weiß, Michael Weller, Matthias Gückenberger +2

    Мақола20173 иқтибос
    ABI

  5. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

    Wanghong Hu, Zhenguo Zi, Yanling Jin +5

    Мақола20183 иқтибос
    ABI

  6. Oncolytic virotherapy

    Stephen J. Russell, Kah-Whye Peng, John C. Bell

    Шарҳ мақола20123 иқтибос
    ABI

  7. Targeting PI3K in cancer: mechanisms and advances in clinical trials

    Jing Yang, Ji Nie, Xuelei Ma +3

    Шарҳ мақола20192 иқтибос
    ABI

  8. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

    Christine E. Brown, Behnam Badie, Michael E. Barish +14

    Мақола20152 иқтибос
    ABI

  9. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

    Sandra Demaria, Bruce Ng, M. Devitt +4

    Мақола20042 иқтибос
    ABI

  10. Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

    Serena Perna, Daria Pagliara, Aruna Mahendravada +4

    Мақола20132 иқтибос
    ABI

  11. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

    Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta +11

    Мақола20162 иқтибос
    ABI

  12. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

    Мақола20162 иқтибос
    ABI

  13. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

    Lenka V. Hurton, Harjeet Singh, Amer Najjar +12

    Мақола20162 иқтибос
    ABI

  14. The ectonucleotidases <scp>CD</scp>39 and <scp>CD</scp>73: Novel checkpoint inhibitor targets

    Bertrand Allard, Maria Serena Longhi, Simon C. Robson +1

    Шарҳ мақола20172 иқтибос
    ABI

  15. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer

    Amanda Rosewell Shaw, Caroline E. Porter, Norihiro Watanabe +5

    Мақола20172 иқтибос
    ABI

  16. CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

    María C. Ramello, Eric B. Haura, Daniel Abate‐Daga

    Мақола20172 иқтибос
    ABI

  17. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines

    Edmund K. Moon, Liang‐Chuan S. Wang, Kheng Bekdache +4

    Мақола20172 иқтибос
    ABI

  18. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

    Мақола20182 иқтибос
    ABI

  19. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

    Mohamed-Reda Benmebarek, Clara H. Karches, Bruno L. Cadilha +3

    Шарҳ мақола20192 иқтибос
    ABI

  20. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

    Frans V. Suurs, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries +1

    Шарҳ мақола20192 иқтибос
    ABI

  21. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

    Darya Alizadeh, Robyn A. Wong, Xin Yang +11

    Мақола20192 иқтибос
    ABI

  22. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

    Margot J. Pont, Tyler Hill, Gabriel O. Cole +14

    Мақола20192 иқтибос
    ABI

  23. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

    Meijun Zheng, Jianhan Huang, Aiping Tong +1

    Шарҳ мақола20192 иқтибос
    ABI

  24. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

    Bryan D. Choi, Xiaoling Yu, Ana P. Castaño +14

    Мақола20192 иқтибос
    ABI

  25. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

    Rachel Grosser, Leonid Cherkassky, Navin K. Chintala +1

    Шарҳ мақола20192 иқтибос
    ABI